Dicerna Pharmaceuticals reported $25.46M in Selling and Administration Expenses for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Selling And Administration Expenses Change
Acceleron Pharma XLRN:US $ 35.47M 4.41M
Agenus AGEN:US $ 16.65M 298K
Alnylam Pharmaceuticals ALNY:US $ 153.82M 1.08M
Amgen AMGN:US $ 1.38B 130M
Arrowhead Research ARWR:US $ 17.86M 1.67M
Biogen BIIB:US $ 654.1M 16.8M
Bluebird Bio BLUE:US $ 78.58M 8.3M
Dicerna Pharmaceuticals DRNA:US $ 25.46M 4.79M
Exelixis EXEL:US $ 98.49M 3.86M
Gilead Sciences GILD:US $ 1.34B 297M
GlaxoSmithKline GSK:LN 2.5B 183M
Immunogen IMGN:US $ 9.73M 481K
Intercept Pharmaceuticals ICPT:US $ 57.65M 1.62M
Intrexon XON:US $ 20M 1.3M
IONIS PHARMACEUT IONS:US $ 56.46M 4.74M
Karyopharm Therapeutics KPTI:US $ 36.53M 1.12M
Lexicon Pharmaceuticals LXRX:US 7.94M 321K
Macrogenics MGNX:US $ 15.23M 198K
Merk MRK:US $ 2.25B 376M
Mirati Therapeutics MRTX:US $ 29.61M 1.26M
Pfizer PFE:US $ 2.79B 134M
Regeneron Pharmaceuticals REGN:US $ 414.7M 9.1M
Regulus Therapeutics RGLS:US $ 2.49M 10K
Ultragenyx Pharmaceutical RARE:US $ 53.41M 152K